Nykode Therapeutics AS (NYKD.OL)
NOK 3.19
(-4.61%)
NOK 3.19
(-4.61%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -35.15 Million USD | 9.64% |
| 2022 | -411.21 Million USD | -408.01% |
| 2021 | -80.94 Million USD | -105.74% |
| 2020 | 1.4 Billion USD | 1269.49% |
| 2019 | -120.55 Million USD | -88.98% |
| 2018 | -63.79 Million NOK | -103.35% |
| 2017 | -31.37 Million NOK | -93.4% |
| 2016 | -16.22 Million NOK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -7.38 Million USD | 50.56% |
| 2024 Q1 | -157.22 Million USD | -179.96% |
| 2023 FY | -371.59 Million USD | 9.64% |
| 2023 Q2 | -98.71 Million USD | 7.02% |
| 2023 Q3 | -107.38 Million USD | -8.79% |
| 2023 Q4 | -57.83 Million USD | 46.14% |
| 2023 Q1 | -106.17 Million USD | 14.63% |
| 2022 Q2 | -82.6 Million NOK | -35.37% |
| 2022 FY | -411.21 Million USD | -408.01% |
| 2022 Q4 | -124.37 Million USD | 16.41% |
| 2022 Q3 | -148.78 Million NOK | -80.11% |
| 2022 Q1 | -61.02 Million NOK | -164.9% |
| 2021 Q4 | 94.03 Million NOK | 244.07% |
| 2021 FY | -80.94 Million USD | -105.74% |
| 2021 Q3 | -65.26 Million NOK | 0.0% |
| 2020 FY | 1.4 Billion USD | 1269.49% |
| 2019 FY | -120.55 Million USD | -88.98% |
| 2018 FY | -63.79 Million NOK | -103.35% |
| 2017 FY | -31.37 Million NOK | -93.4% |
| 2016 FY | -16.22 Million NOK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arctic Bioscience AS | -45.51 Million NOK | 22.763% |
| Aqua Bio Technology ASA | -19.11 Million NOK | -83.929% |
| ArcticZymes Technologies ASA | 19.42 Million NOK | 280.973% |
| BerGenBio ASA | -190.4 Million NOK | 81.537% |
| Hofseth BioCare ASA | -106.68 Million NOK | 67.048% |
| PCI Biotech Holding ASA | -20.31 Million NOK | -73.045% |
| Thor Medical ASA | -26.56 Million NOK | -32.352% |
| Ultimovacs ASA | -189.23 Million NOK | 81.423% |